Breast Cancer and Battlestar Galactica

Rob Quinn Joins the Company to Leverage His Extensive Clinical Software Experience to Lead the Product Marketing Function, WorldwideWOBURN, Mass. and Ashtead, UK – September 26, 2017 – BridgeHead Software, a leader in healthcare data management, today announced the addition of Rob Quinn to lead Global Product Marketing. He brings more than 15 years’ experience in healthcare IT product marketing and will be instrumental in driving BridgeHead’s solution strategy and go-to-market initiatives. “Just as today’s hospitals are striving for better engagement with their patient populations, Rob will drive our efforts toward more frequent, outcome-based communications with our customers on a global scale,” said Michael Ball, chief business development officer. “Beyond his expertise in product marketing, he is well versed in clinical applications, cloud-based services, agile product design and delivery, and rapid validation – that will be invaluable to the company in the months and years ahead.”A

London, 7 November 2017 - West Berkshire estate agents Jones Robinson has announced it will give another £10,000 via The Good Exchange’s on-line matching platform to help the Rosemary Appeal get closer to its fundraising target to build a new cancer centre and renal dialysis unit at West Berkshire Hospital.The £10,000 gift, which is in addition to the £10,000 already generously donated, is being awarded as match funding through The Good Exchange on-line funder/fundraiser matching platform, which means all donations made to the Rosemary Appeal through The Good Exchange will be doubled, effectively turning £10,000 into £20,000.Newbury and Thatcham Hospital Buildings Trust and Newbury Cancer Care Trust have already raised over £3m in just 12 months. But the appeal still needs to raise another £1.6m and is looking for charitable trusts, corporate sponsors and individual donors and fundraisers to help. Colin Weatherup, fundraiser and spokesman for The Rosemary Appeal said: “We are extremely

CE-IVD labeled PAXgene® Blood ccfDNA tube will be available in Western Europe FRANKLIN LAKES, N.J. and EYSINS, SWITZERLAND, February 21, 2018 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial availability of the CE-IVD marked PAXgene® Blood ccfDNA tube within the European Economic Area and Switzerland (Western Europe). The plastic blood collection tube, which includes a proprietary sample stabilization additive and BD Vacutainer® Hemogard™ technology to help protect healthcare worker safety, was designed to ensure accurate and reproducible results in molecular diagnostic testing applications using circulating cell-free DNA (ccfDNA), such as cancer and non-invasive prenatal tests. The product was developed by PreAnalytiX GmbH, a joint venture between BD and QIAGEN. Cells, including fetal cells, tumor cells, or cells from transplanted organs, release DNA into the blood stream. This DNA can be analyzed using PCR o

But the real winner is dataLondon, 5 August 2019 – Marketing data and insight agency REaD Group has further cemented its success in data-driven and insight marketing after winning a number of awards at two separate industry events, and being shortlisted for a further three categories in a third.Alongside Marie Curie, REaD Group was named as winner of the Best Use of Insight Award at the IoF National Fundraising Awards on 2nd July for the Big SHIFT project. The National Fundraising Awards celebrate the very best in fundraising and are a unique opportunity to showcase excellence in the charity fundraising sector.The award follows swiftly on the heels of REaD’s win at the Insight in Fundraising Awards in June. Together with Marie Curie, REaD took home the Most Powerful Insight using Data Analysis award. The awards recognise the best work, innovation and inspirational stories of individuals working in data, analysis and insight contributing to fundraising practices.REaD was also shortliste

World’s leading experts gather in Seville to discuss the fastest growing health epidemic in Europe now affecting 1 in 4 people.26 September 2019 – Seville, Spain The Non-Alcoholic Fatty Liver Disease prevalence in Europe is a preventable epidemic, leading researchers will report at the EASL Non-Alcoholic Fatty Liver Disease (NAFLD) Summit 2019 taking place this week in Seville, Spain.More than half of adults and one third of children in Europe are classified as overweight or obese, with the highest proportion coming from lower socio-economic groups where NAFLD is prevalent. NAFLD is the accumulation of excess fat in the liver and is now the most common cause of liver disease in Western countries due to the rapid rise in levels of obesity and type 2 diabetes. It is a major European health burden resulting in liver cirrhosis and liver cancer, as well as big increases in cardiovascular disease and non-liver cancers.Lack of physical activity and excess calorie intake leads to weight gain a

Hitachi, Ltd. (TSE:6501, “Hitachi”) and Centre Léon Bérard (CLB), a leading French Comprehensive Cancer Center in Lyon-France, announced today that they have entered into an agreement to jointly promote research and development aimed at improving the efficiency of diagnosis and treatment of cancer and established a new research laboratory called Hitachi Lyon Lab on the CLB site, starting November 5th.In this collaboration, Hitachi and CLB will conduct research and development of novel technologies to detect and diagnose cancers exploiting medical images such as CT/MRI using artificial intelligence (AI) and to predict response to radiation therapy using tumor genomic and transcriptomic data.According to statistics from the Organization for Economic Co-operation and Development (OECD), Japan has the largest number of CTs and MRIs per million people. With the improvements of diagnostic imaging equipment, the number of images read by radiologists is increasing, and technologies that reduce

Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate (ADC) under their existing license and collaboration agreement. NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of this second undisclosed target. The development will be based on NBE’s proprietary antibody drug conjugate platform, including NBE’s site-specific SMAC-technology™ conjugation and its new, highly potent anthracycline toxin platforms. SOTIO will take global responsibility for clinical development, registration and commercialization of the ADC products.NBE-Therapeutics’ new iADC™ platform creates highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect. It has shown unprecedented preclinical data in efficacy, as well as safety, in multi

Reading, UK. February 20, 2020 – IGEL, provider of the next-gen edge OS for cloud workspaces, today announced that Anthony Nolan, the pioneering blood cancer charity, has implemented UD3 desktops to support an organizational-wide implementation of Windows 10 and provide rich multimedia capability for over 300 employees. This will boost collaboration and teamwork by enabling geographically dispersed staff to, among other things, set up video-based conference calls to work more productively. Founded in 1974, Anthony Nolan is a charity that makes lifesaving connections between people with blood cancer and incredible strangers ready to donate their stem cells. Every day, its register of more than 780,000 people gives families a future. And it’s a significant problem. Every 14 minutes, someone is diagnosed with blood cancer such as leukemia, lymphoma or myeloma. This meant that, last year, Anthony Nolan helped over 1,400 patients receive a second chance of life. A long term user of v

Greenham Trust pledges £500,000 of match-funding; the new centre will improve access to traditional and supportive cancer care in the local areaNewbury, 18th January 2018 – Not-for-profit, The Good Exchange, has provided key support to Ark Cancer Centre Charity’s mission to raise £5million to help build a state-of-the-art cancer treatment centre.Largely being funded by Hampshire Hospitals NHS Foundation Trust (HHFT), the new centre will improve and enhance the cancer patient’s journey, providing chemotherapy, radiotherapy, complementary treatments and supportive services in a calm and uplifting environment.The majority of HHFT cancer patients currently have to travel to Southampton or Guildford to receive radiotherapy, but the new centre – which will probably be built on the existing Basingstoke hospital site – will bring this treatment closer to home for more people. By providing radiotherapy and other services under one roof, the centre will be a beacon facility.The offer of £500,000

New long-term results from the international TARGIT-A breast cancer study, based on ZEISS technology, have been published[1] JENA/ GERMANY, August 27, 2020 Use of targeted intra-operative radiotherapy (TARGIT), as a single dose - with ZEISS INTRABEAM - directly after removal of a tumor, confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). Within the accuracy of the study, the risk of a local tumor recurrence in the breast is similar and non-breast cancer death is reduced. The TARGIT-A randomized, multi-center phase 3 study involving 2298 patients with a median patient follow-up time of 8.6 years meets the highest scientific standards. Globally more than 40,000 patients have already been treated, in over 350 breast cancer centers, with the TARGIT method. "Single dose intra-operative radiotherapy for early stage breast cancer can be a better alternative to conventional whole breast radiotherapy for most patients during primary tumor management " st